Biotech Values

[DewDiligence]

>VRTX – At week 12, the differences in the C208 trial between the Pegasys and Pegintron arms are gone and TID looks better than BID.<

The big question: How many percentage points of SVR should VRTX and JNJ be willing to sacrifice for BID rather than a TID administration? I have an opinion, but I’d like to get yours (and other posters’) before I reveal it.